Use of olanzapine in the treatment of bipolar I disorder

References

• Barnes TR, McPhillips MA. Critical analysis and comparison of the side effect and safety profiles of the new antipsychotics. BE j PTchiatry38(Suppl.), 34–43 (1999).
   Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. j Psychiatry158(3), 360–369 (2001).
   Google Scholar
• Nasrallah HA, Cchurchill CM, Hamdan- Allan CM. Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am. j Psychiatry 145(11), 1455–1456 (1988).
   Google Scholar
• Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch. Gen fiychiatry39(4), 473–481 (1982).
   Google Scholar
• Tamminga CA. The science of antipsychotics: mechanistic insight. CNS Specn 8(11 Suppl. 2), 5–9 (2003).
   Google Scholar
• Di Matteo V, Di Mascio M, Di Giovanni G, Esposito E. Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors. Psychopharmacology 150(1), 45–51 (2000).
   Google Scholar
• Meltzer HY, Arvanitis L, Bauer D, Rein W Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Arm fiychiatry161(6), 975–984 (2004).
   PubMed Web of Science ®Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics.j Clin. PTchiatry57\(Suppl. 11), 12–25 (1996).
   Google Scholar
• Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am. PTchiatry144(11), 1403–1411 (1987).
   PubMed Web of Science ®Google Scholar
• Tohen M, Jacobs TG, Grundy SL et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch. Gen. PTchiatry57(9), 841–849 (2000).
   Google Scholar
• ••One of two studies that demonstrates theefficacy of olanzapine in the treatment of bipolar mania. The two studies allowed olanzapineto be approved by the Food and Drug Administration for this indication.
   Google Scholar
• Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. PTchiatry156(5), 702–709 (1999).
   Google Scholar
• Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen PTchiatry30(2), 229–233 (1974).
   PubMed Web of Science ®Google Scholar
• Shi L, Namjoshi MA, Zhang F et al. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status. Int. Clin. PTchopharmacol 17(5), 227–237 (2002).
   Google Scholar
• Baldessarini RJ, Hennen J, Wilson M et al. Olanzapine versus placebo in acute mania: treatment responses in subgroups. J. Clin. Psychopharmacol 23(4), 370–376 (2003).
   Google Scholar
• •Subgroup analysis of the original bipolar mania registration trials that demonstrate olanzapine's efficacy in a wide variety of bipolar subtypes.
   Google Scholar
• Tohen M, Zhang F, Taylor CC et al. A meta-analysis of the use of typical antipsychotic agents in bipolar disorder. Affect. Disonl 65(1), 85–93 (2001).
   PubMedGoogle Scholar
• Tohen M, Zarate CA Jr. Antipsychotic agents and bipolar disorder. j Clin. Psychiaby59\(Suppl. 1), 38–49 (1998).
   Google Scholar
• Zarate CA Jr. Antipsychotic drug side effect issues in bipolar manic patients. Clin. PTchiatry 61 (Suppl. 8), 52–63 (2000).
   Google Scholar
• Tohen M, Baker RVV, Altshuler LL et al Olanzapine versus divalproex in the treatment of acute mania. Am. j Psychiatry 159(6), 1011–1017 (2002).
   PubMed Web of Science ®Google Scholar
• •Direct comparison with divalproex that showed olanzapine to be at least as effective in bipolar disorder with some possible advantages.
   Google Scholar
• Zajecka JM, Weisler R, Sachs G et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. j Clin. PTchiatry63(12), 1148–1155 (2002).
   Google Scholar
• •Found olanzapine and divalproex to be equally efficacious, but concludes that divalproex has a better tolerability.
   Google Scholar
• Wang P, Ketter T Emerging roles of new antipsychotics in bipolar disorders. C1.117: Psych. Ther. Rep. 1(2), 55–61 (2003).
   Google Scholar
• Vieta E. Divalproex versus olanzapine in mania." Clin. Psychiatry64(10), 1266–1267 (2003).
   Google Scholar
• Tohen M, Chengappa KN, Suppes T et al Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. fiychiatry59(1), 62–69 (2002).
   Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ et al Current research on rapid cycling bipolar disorder and its treatment. j Affect. Disonl 67(1-3), 241–55 (2001).
   Google Scholar
• Judd LL, Schettler PJ, Akiskal HS et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. Neuropsychopharmacol 6(2), 127–137 (2003). Over 200 patients with bipolar disorder were followed for up to 20 years to evaluate the phenomenology of the disease. The results indicated that symptoms are more chronic than episodic and overwhelmingly depressive in nature.
   Google Scholar
• Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen Psychiatry 60(11), 1079–1088 (2003).
   PubMed Web of Science ®Google Scholar
• ••Demonstrated the safety and efficacy of the olanzapine—fluoxetine combination in the treatment of bipolar depression.
   Google Scholar
• Goodwin FK, Jamison KR. Manic- Depressive illness. Oxford University Press, NY, USA (1990).
   Google Scholar
• Faravelli C, Ambonetti A, Pallanti S, Pazzagli A. Depressive relapses and incomplete recovery from index episode. Am. PTchiatry143(7), 888–891 (1986).
   PubMed Web of Science ®Google Scholar
• Sanger TM, Grundy SL, Gibson PJ et al Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. j Clin. fiychiatry62(4), 273–281 (2001).
   Google Scholar
• Tohen M, Ketter TA, Zarate CA et al Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am. J. PFhiatry160(7), 1263–1271 (2003).
   Google Scholar
• Tohen M, Marneros A, Bowden C et al Olanzapine versus lithium in relapse prevention in bipolar disorder. Presented at the American BychMtric Association Annual Meeting, CA, USA (2003).
   Google Scholar
• Keck PE Jr, McElroy SL, Tugrul KC, Bennett JA. Valproate oral loading in the treatment of acute mania. j Clin. Psychiatry 54(8), 305–308 (1993).
   Google Scholar
• Hirschfeld RM, Baker JD, Wozniak P, Tracy K, Sommerville KW The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. j Clin. Psychiatry 64(7), 841–846 (2003).
   Google Scholar
• Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. j Psychiatry 161 (2), 217–222 (2004).
   Google Scholar
• Tohen M, Chengappa KN, Suppes T et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser versus mood stabiliser alone. Br. fiychiatry184,337–345 (2004).
   Google Scholar
• National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health, National Heart, Lung and Blood Institute, MD, USA (2001).
   Google Scholar
• Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 15 (7), 537–551 (2001).
   PubMed Web of Science ®Google Scholar
• Daniel DG. Tolerability of ziprasidone: an expanding perspective. j Clin. Bychiatry 64\(Suppl. 19), 40–49 (2003).
   Google Scholar
• Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. j Clin. Psychiatry64(1), 60–62 (2003).
   Google Scholar
• DeLeon A, Patel NC, Lynn Crismon M. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 26(5), 649–666 (2004).
   Google Scholar
• Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RII, Nasrallah HA. Differentialeffects of risperidone, olanzapine, clozapine, and conventional antipsychotics on Type 2 diabetes: findings from a large health plan database. j Clin. Psychiatry 63(10), 920–30 (2002).
   Google Scholar
• Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J. Clin. PFhiatry63\(Suppl. 4), 12–19 (2002).
   Google Scholar
• Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Arn. I PFhiatry154(9), 1248–1254 (1997).
   PubMed Web of Science ®Google Scholar
• Beasley CM, Dellva MA,Tamura RN et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br. PFhiatry174,23–30 (1999).
   Google Scholar
• Kennedy JS, Bymaster FP, Schuh L et al A current review of olanzapine's safety in the geriatric patient: from preclinical pharmacology to clinical data. int. j Ceriatr Bychiatry16\(Suppl. 1), S33—S61 (2001).
   Google Scholar
• Ghaemi SN, Rosenquist KJ, Ko JY et al Antidepressant treatment in bipolar versus unipolar depression. Am. j Psychiatry 161(1), 163–165 (2004).
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAIVIA 288(14), 1723–1727 (2002).
   Google Scholar
• Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Cam 27(2), 596–601 (2004).
   Google Scholar
• •Concern over the adverse effects of the atypical antipsychotics on weight, lipids and other cardiovascular risk factors led to the development of this consensus statement by the American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity
   Google Scholar